Johnson & Johnson $JNJ Stock Position Decreased by Te Ahumairangi Investment Management Ltd

Te Ahumairangi Investment Management Ltd trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 8.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 50,295 shares of the company’s stock after selling 4,540 shares during the quarter. Johnson & Johnson makes up 1.6% of Te Ahumairangi Investment Management Ltd’s holdings, making the stock its 15th largest holding. Te Ahumairangi Investment Management Ltd’s holdings in Johnson & Johnson were worth $9,326,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. AustralianSuper Pty Ltd lifted its position in shares of Johnson & Johnson by 632.0% in the 3rd quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company’s stock valued at $16,536,000 after acquiring an additional 77,000 shares in the last quarter. J.W. Cole Advisors Inc. grew its position in Johnson & Johnson by 2.2% during the 3rd quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company’s stock worth $24,278,000 after purchasing an additional 2,769 shares in the last quarter. Guinness Asset Management LTD raised its stake in Johnson & Johnson by 0.4% during the 3rd quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company’s stock valued at $251,216,000 after purchasing an additional 5,994 shares during the period. Treasurer of the State of North Carolina raised its stake in Johnson & Johnson by 8.3% during the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock valued at $188,638,000 after purchasing an additional 94,957 shares during the period. Finally, National Pension Service lifted its holdings in shares of Johnson & Johnson by 3.2% in the third quarter. National Pension Service now owns 4,926,569 shares of the company’s stock valued at $913,484,000 after purchasing an additional 151,707 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 22,623 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the transaction, the executive vice president owned 26,769 shares of the company’s stock, valued at approximately $6,540,469.77. This trade represents a 45.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 30,142 shares of company stock worth $7,360,528 in the last 90 days. 0.16% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approval for the TECNIS PureSee intraocular lens — a new premium cataract IOL that expands J&J’s surgical portfolio and could help near‑term revenue and margin mix in vision care. Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens
• Positive Sentiment: Citigroup raises its price target to $274 and sets a Buy rating — a notable upside revision that suggests Street analysts see more earnings/pipeline upside, which can attract buy interest. Johnson & Johnson (NYSE:JNJ) Stock Price Expected to Rise, Citigroup Analyst Says
• Positive Sentiment: BofA lifted its price target (to $253) citing pipeline growth — another institutional nod that supports a higher fair value and reassures investors on forward revenue. BofA Raises Johnson & Johnson (JNJ) Price Target on Pipeline Growth
• Positive Sentiment: JNJ seeks EMA label expansion for Tecvayli in multiple myeloma — regulatory progress on high‑value oncology assets supports longer‑term revenue and valuation upside. JNJ Seeks Label Expansion of Multiple Myeloma Drug Tecvayli in the EU
• Positive Sentiment: Investor lists and dividend articles (Dividend Kings / Best Dividend Stocks) continue to highlight J&J’s defensive yield and dividend reliability, supporting demand from income‑focused investors. The 5 Safest Dividend Kings Are the Only Stocks to Buy Now
• Neutral Sentiment: Barclays reaffirmed its Hold rating — keeps some analyst distribution around a cautious stance despite other upgrades. Barclays Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)
• Neutral Sentiment: Analyst notes and valuation updates show modest revisions to fair value as Street remodels pipeline product by product — directionally supportive but not uniformly bullish. How The Johnson & Johnson (JNJ) Narrative Is Shifting With Pipeline Rethinks And New Valuation Targets

Johnson & Johnson Stock Up 0.7%

Shares of NYSE JNJ traded up $1.70 during mid-day trading on Friday, reaching $243.74. The company had a trading volume of 1,938,400 shares, compared to its average volume of 9,012,237. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $251.71. The stock’s 50 day moving average is $231.22 and its 200-day moving average is $205.79. The stock has a market capitalization of $587.39 billion, a PE ratio of 22.05, a price-to-earnings-growth ratio of 2.40 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The firm had revenue of $24.28 billion during the quarter. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson’s payout ratio is presently 47.06%.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on JNJ shares. Scotiabank reiterated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. Wall Street Zen downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Wednesday, January 28th. Freedom Capital cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 16th. Finally, Leerink Partners increased their price target on shares of Johnson & Johnson from $201.00 to $232.00 and gave the stock a “market perform” rating in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $235.91.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.